Clinical trials: Melanoma Cancer
Cutaneous Melanoma, Synovial Sarcoma
ACTengine® IMA203 Combined With mRNA-4203
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203.
- Trial name
- NCT06946225
- Testing
- IMA203, mRNA-4203
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Immatics US, Inc.
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Melanoma
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.
- Trial name
- MELODY-1 (NCT06540391)
- Testing
- MB097, Pembrolizumab, Vancomycin
- Where
- 19 sites in France, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Microbiotica Ltd
Melanoma
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.
- Trial name
- NCT02975700
- Testing
- PLX3397
- Where
- 5 sites in China, South Korea
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Melanoma, Non-melanoma Skin Cancer
DERM Health Economics Study
This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve…
- Trial name
- NCT04123678
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Skin Analytics Limited
Melanoma
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF…
- Trial name
- NCT04489433
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed.
- Trial name
- NCT02780089
- Where
- 66 sites in United States
- Volunteers
- 408 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
This study was conducted to compare survival using pembrolizumab (SCH 900475, MK-3475) or standard chemotherapy in participants with advanced melanoma (MEL) who had progressed after prior therapy.
- Trial name
- NCT01704287
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00023647
- Testing
- Synchrotope TA2M
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mannkind Corporation
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Melanoma, Advanced Solid Tumor
A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive).
- Trial name
- NCT07107178
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Melanoma
Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma
Evaluation of safety and tolerability of four intradermal injections given at two week intervals. In addition the efficacy of transferrinfection was determined by quantifying Interleukin 2 (IL-2), which was locally produced by…
- Trial name
- NCT02203864
- Testing
- BIBW2 component A, BIBW2 component B
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Stage IV Melanoma
A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)
The purpose of the study is to determine the safety and tolerability of two doses of Coxsackievirus A21, administered 48 hours apart into a superficial melanoma tumour.
- Trial name
- NCT00438009
- Testing
- Coxsackievirus A21
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Viralytics
NSCLC, Melanoma
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
- Trial name
- NCT05180799
- Testing
- BA3071, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Australia
- Volunteers
- 320 people
- Sponsor
- BioAtla, Inc.
Advanced Solid Tumor
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid…
- Trial name
- NCT06249048
- Testing
- STX-001, Keytruda®
- Where
- 7 sites in United States, Australia
- Volunteers
- 108 people
- Sponsor
- Strand Therapeutics Inc.
Uveal Melanoma, Ocular Melanoma
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT04417530
- Testing
- AU-011, Suprachoroidal Microinjector, PDT Laser
- Where
- 22 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aura Biosciences
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Lung Cancer, Ovarian Cancer
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next…
- Conditions
- Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer
- Trial name
- PREFER (NCT05697198)
- Testing
- OmniSeq Test
- Where
- 8 sites in United States
- Volunteers
- 1,429 people
- Sponsor
- Labcorp Corporation of America Holdings, Inc
Melanoma
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Previous studies suggests that M-Vax, a melanoma vaccine prepared from patients own cancer cells, can stimulated patients' immune system to react against their cancer.
- Trial name
- NCT00477906
- Testing
- M-Vax- autologous, hapten-modified melanoma vaccine
- Volunteers
- 387 people
- Sponsor
- AVAX Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.